221 related articles for article (PubMed ID: 21659760)
1. Transforming growth factor-β and Smads.
Lan HY; Chung ACK
Contrib Nephrol; 2011; 170():75-82. PubMed ID: 21659760
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
Lan HY
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
[TBL] [Abstract][Full Text] [Related]
3. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
[TBL] [Abstract][Full Text] [Related]
4. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation.
Lan HY
Int J Biol Sci; 2011; 7(7):1056-67. PubMed ID: 21927575
[TBL] [Abstract][Full Text] [Related]
5. TGF-β/Smad signaling in kidney disease.
Lan HY; Chung AC
Semin Nephrol; 2012 May; 32(3):236-43. PubMed ID: 22835454
[TBL] [Abstract][Full Text] [Related]
6. [The Role of TGF-β1/SMAD in Diabetic Nephropathy: Mechanisms and Research Development].
Wang Y; Guo J; Shao B; Chen H; Lan H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1065-1073. PubMed ID: 38162063
[TBL] [Abstract][Full Text] [Related]
7. TGF-Beta as a Master Regulator of Diabetic Nephropathy.
Wang L; Wang HL; Liu TT; Lan HY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360646
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta and Smad signalling in kidney diseases.
Wang W; Koka V; Lan HY
Nephrology (Carlton); 2005 Feb; 10(1):48-56. PubMed ID: 15705182
[TBL] [Abstract][Full Text] [Related]
9. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy.
Wang JY; Gao YB; Zhang N; Zou DW; Wang P; Zhu ZY; Li JY; Zhou SN; Wang SC; Wang YY; Yang JK
Mol Cell Endocrinol; 2014 Jul; 392(1-2):163-72. PubMed ID: 24887517
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory smads and tgf-Beta signaling in glomerular cells.
Schiffer M; Schiffer LE; Gupta A; Shaw AS; Roberts IS; Mundel P; Böttinger EP
J Am Soc Nephrol; 2002 Nov; 13(11):2657-66. PubMed ID: 12397035
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
Li JH; Huang XR; Zhu HJ; Oldfield M; Cooper M; Truong LD; Johnson RJ; Lan HY
FASEB J; 2004 Jan; 18(1):176-8. PubMed ID: 12709399
[TBL] [Abstract][Full Text] [Related]
12. Role of the TGF-β/BMP-7/Smad pathways in renal diseases.
Meng XM; Chung AC; Lan HY
Clin Sci (Lond); 2013 Feb; 124(4):243-54. PubMed ID: 23126427
[TBL] [Abstract][Full Text] [Related]
13. Xiaokeping mixture inhibits diabetic nephropathy in streptozotocin-induced rats through blocking TGF-β1/Smad7 signaling.
Xin C; Xia Z; Jiang C; Lin M; Li G
Drug Des Devel Ther; 2015; 9():6269-74. PubMed ID: 26664048
[TBL] [Abstract][Full Text] [Related]
14. TGF-β/Smad signaling in renal fibrosis.
Meng XM; Tang PM; Li J; Lan HY
Front Physiol; 2015; 6():82. PubMed ID: 25852569
[TBL] [Abstract][Full Text] [Related]
15. Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy.
Tang F; Hao Y; Zhang X; Qin J
Drug Des Devel Ther; 2017; 11():2813-2826. PubMed ID: 29033543
[TBL] [Abstract][Full Text] [Related]
16. Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.
Okazaki Y; Yamasaki Y; Uchida HA; Okamoto K; Satoh M; Maruyama K; Maeshima Y; Sugiyama H; Sugaya T; Kashihara N; Makino H
Clin Exp Nephrol; 2007 Mar; 11(1):77-87. PubMed ID: 17385003
[TBL] [Abstract][Full Text] [Related]
17. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
McClelland AD; Herman-Edelstein M; Komers R; Jha JC; Winbanks CE; Hagiwara S; Gregorevic P; Kantharidis P; Cooper ME
Clin Sci (Lond); 2015 Dec; 129(12):1237-49. PubMed ID: 26415649
[TBL] [Abstract][Full Text] [Related]
18. Smads as therapeutic targets for chronic kidney disease.
Lan HY
Kidney Res Clin Pract; 2012 Mar; 31(1):4-11. PubMed ID: 26889404
[TBL] [Abstract][Full Text] [Related]
19. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells.
Isono M; Chen S; Hong SW; Iglesias-de la Cruz MC; Ziyadeh FN
Biochem Biophys Res Commun; 2002 Sep; 296(5):1356-65. PubMed ID: 12207925
[TBL] [Abstract][Full Text] [Related]
20. Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway.
Li Z; Hong Z; Peng Z; Zhao Y; Shao R
Hum Cell; 2018 Jul; 31(3):199-209. PubMed ID: 29549584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
